Epidemic history and evolution of an emerging threat of international concern, the severe acute respiratory syndrome coronavirus 2

This comprehensive review focuses on the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and its impact as the cause of the COVID‐19 pandemic. Its objective is to provide a cohesive overview of the epidemic history and evolutionary aspects of the virus, with a particular emphasis on its emergence, global spread, and implications for public health. The review delves into the timelines and key milestones of SARS‐CoV‐2's epidemiological progression, shedding light on the challenges encountered during early containment efforts and subsequent waves of transmission. Understanding the evolutionary dynamics of the virus is crucial in monitoring its potential for adaptation and future outbreaks. Genetic characterization of SARS‐CoV‐2 is discussed, with a focus on the emergence of new variants and their implications for transmissibility, severity, and immune evasion. The review highlights the important role of genomic surveillance in tracking viral mutations linked to establishing public health interventions. By analyzing the origins, global spread, and genetic evolution of SARS‐CoV‐2, valuable insights can be gained for the development of effective control measures, improvement of pandemic preparedness, and addressing future emerging infectious diseases of international concern.

[1]  P. Simmonds,et al.  The evolution of SARS-CoV-2 , 2023, Nature Reviews Microbiology.

[2]  A. Maruotti,et al.  Is a new COVID‐19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data , 2023, Journal of medical virology.

[3]  K. Joyal-Desmarais,et al.  Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022 , 2023, The Lancet Respiratory Medicine.

[4]  William T. Harvey,et al.  SARS-CoV-2 variant biology: immune escape, transmission and fitness , 2023, Nature Reviews Microbiology.

[5]  Madhukiran Parvathaneni,et al.  A Review on Strategies for COVID-19 Vaccine Development and Regulatory Requirements , 2023, Journal of Drug Delivery and Therapeutics.

[6]  S. Kashima,et al.  Global SARS-CoV-2 genomic surveillance: What we have learned (so far) , 2023, Infection, Genetics and Evolution.

[7]  Xuping Xie,et al.  Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster , 2022, Nature Medicine.

[8]  N. Kitchin,et al.  Improved Neutralization of Omicron BA.4/5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent BA.4/5 Vaccine , 2022, bioRxiv.

[9]  Xuping Xie,et al.  Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mRNA vaccine or a BA.5-bivalent booster , 2022, bioRxiv.

[10]  E. C. Mattos,et al.  Genomic epidemiology of the SARS-CoV-2 epidemic in Brazil , 2022, Nature Microbiology.

[11]  Sahil Kumar,et al.  Recent advances in the vaccine development for the prophylaxis of SARS Covid-19 , 2022, International Immunopharmacology.

[12]  E. M. Souza,et al.  Optical Biosensor for the Detection of Infectious Diseases Using the Copolymer F8T2 with Application to COVID-19 , 2022, Sensors.

[13]  G. Whittaker,et al.  Intrinsic furin-mediated cleavability of the spike S1/S2 site from SARS-CoV-2 variant B.1.1.529 (Omicron) , 2022, bioRxiv.

[14]  S. Khoshnood,et al.  A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19 , 2022, Frontiers in Microbiology.

[15]  William T. Harvey,et al.  SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway , 2022, Nature Microbiology.

[16]  O. Pybus,et al.  Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa , 2022, Nature Medicine.

[17]  Jiming Zhang,et al.  SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance , 2022, Frontiers in Immunology.

[18]  Irena Vlatkovic,et al.  COVID-19 mRNA vaccines: Platforms and current developments , 2022, Molecular Therapy.

[19]  S. Zeger,et al.  Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression , 2022, The Lancet.

[20]  E. Kenawy,et al.  Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic , 2022, International Journal of Biological Macromolecules.

[21]  D. Ivanković,et al.  The experiences of 33 national COVID-19 dashboard teams during the first year of the pandemic in the World Health Organization European Region: A qualitative study , 2022, Digital health.

[22]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[23]  M. Kraemer,et al.  Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa , 2021, Nature.

[24]  S. Maurer-Stroh,et al.  GISAID’s Role in Pandemic Response , 2021, China CDC weekly.

[25]  Wenling Zhang,et al.  The screening value of RT-LAMP and RT-PCR in the diagnosis of COVID-19: systematic review and meta-analysis , 2021, Journal of Virological Methods.

[26]  D. Barouch,et al.  COVID-19 Vaccines: Adenoviral Vectors. , 2021, Annual review of medicine.

[27]  M. Kraemer,et al.  Sharing, synthesis and sustainability of data analysis for epidemic preparedness in Europe , 2021, The Lancet Regional Health - Europe.

[28]  Z. Ning,et al.  Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies , 2021, PLoS pathogens.

[29]  A. Yılmaz,et al.  Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey , 2021, The Lancet.

[30]  T. Stadler,et al.  CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants , 2021, Bioinform..

[31]  Carla A. Cummins,et al.  The COVID-19 Data Portal: accelerating SARS-CoV-2 and COVID-19 research through rapid open access data sharing , 2021, Nucleic Acids Res..

[32]  J. Munita,et al.  Longitudinal assessment of SARS-CoV-2 IgG seroconversionamong front-line healthcare workers during the first wave of the Covid-19 pandemic at a tertiary-care hospital in Chile , 2021, BMC Infectious Diseases.

[33]  M. Giacca,et al.  The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets , 2021, Nature Microbiology.

[34]  H. Harapan,et al.  Global prevalence of prolonged gastrointestinal symptoms in COVID-19 survivors and potential pathogenesis: A systematic review and meta-analysis , 2021, F1000Research.

[35]  M. Suchard,et al.  Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil , 2021, Science.

[36]  A. Fauci The story behind COVID-19 vaccines , 2021, Science.

[37]  M. Aoki,et al.  Essential properties and pitfalls of colorimetric Reverse Transcription Loop-mediated Isothermal Amplification as a point-of-care test for SARS-CoV-2 diagnosis , 2021, Molecular medicine.

[38]  Yan Liu,et al.  Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials , 2021, The Lancet Infectious Diseases.

[39]  Sergei L. Kosakovsky Pond,et al.  Detection of a SARS-CoV-2 variant of concern in South Africa , 2021, Nature.

[40]  M. Meyer,et al.  Point-of-care bulk testing for SARS-CoV-2 by combining hybridization capture with improved colorimetric LAMP , 2021, Nature Communications.

[41]  Jie Zhou,et al.  Increased transmission of SARS-CoV-2 lineage B.1.1.7 (VOC 2020212/01) is not accounted for by a replicative advantage in primary airway cells or antibody escape , 2021, bioRxiv.

[42]  J. Montclare,et al.  Protein-based lateral flow assays for COVID-19 detection , 2021, Protein engineering, design & selection : PEDS.

[43]  M. Biggerstaff,et al.  Emergence of SARS-CoV-2 B.1.1.7 Lineage — United States, December 29, 2020–January 12, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[44]  N. Patel,et al.  SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice , 2021, Nature Communications.

[45]  John S. Brownstein,et al.  Data curation during a pandemic and lessons learned from COVID-19 , 2021, Nature Computational Science.

[46]  Haiyong Peng,et al.  SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity , 2020, Nature Communications.

[47]  Wenling Wang,et al.  Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial , 2020, The Lancet Infectious Diseases.

[48]  Sarah K. Hilton,et al.  Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding , 2020, Cell.

[49]  S. Scarpino,et al.  Applications of predictive modelling early in the COVID-19 epidemic , 2020, The Lancet Digital Health.

[50]  R. McIntyre,et al.  Impact of COVID-19 pandemic on mental health in the general population: A systematic review , 2020, Journal of Affective Disorders.

[51]  Cynthia Liu,et al.  Assay Techniques and Test Development for COVID-19 Diagnosis , 2020, ACS central science.

[52]  Oren Etzioni,et al.  CORD-19: The Covid-19 Open Research Dataset , 2020, NLPCOVID19.

[53]  M. Ciccozzi,et al.  The 2019‐new coronavirus epidemic: Evidence for virus evolution , 2020, bioRxiv.

[54]  Trevor Bedford,et al.  Nextstrain: real-time tracking of pathogen evolution , 2017, bioRxiv.

[55]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[56]  anonymous Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in the EU/EEA and the UK – seventh update , 2020 .